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Abstract
Purpose: The aim of this study was to investigate the variability in quantitative
performance and feasibility of quantitative harmonisation in 89Zr PET/CT imaging.
Methods: Eight EANM EARL-accredited (Kaalep A et al., Eur J Nucl Med Mol Imaging
45:412–22, 2018) PET/CT systems were investigated using phantom acquisitions of
uniform and NEMA NU2-2007 body phantoms. The phantoms were filled according
to EANM EARL guidelines for [18F]FDG, but [18F]FDG solution was replaced by a 89Zr
calibration mixture. For each system, standard uptake value (SUV) accuracy and
recovery coefficients (RC) using SUVmean, SUVmax and SUVpeak metrics were
determined.
Results: All eight investigated systems demonstrated similarly shaped RC curves, and
five of them exhibited closely aligning recoveries when SUV bias correction was
applied. From the evaluated metrics, SUVpeak was found to be least sensitive to
noise and reconstruction differences among different systems.
Conclusions: Harmonisation of PET/CT scanners for quantitative 89Zr studies is
feasible when proper scanner-dose calibrator cross-calibration and harmonised
image reconstruction procedures are followed. An accreditation programme for PET/
CT scanners would facilitate multicentre 89Zr quantitative studies.
Keywords: 89Zr, Performance, Harmonisation, PET/CT, Quantification, EARL accreditation
Introduction
The use of radiolabelled antibodies for diagnostic and therapeutic purposes has been
going on for more than 50 years [1]. Their application as imaging probes in positron
emission tomography (PET) combines the high sensitivity of PET with the high antigen
specificity of monoclonal antibodies [2]. 89Zr-based tracers are becoming widespread
with increasingly available supply, advances in radiochemistry and successful pilot
studies in humans. However, multicentre studies using 18F-labelled tracers have dem-
onstrated the need for standardisation of image acquisition, reconstruction, and ana-
lysis procedures and international harmonisation programmes such as EANM and
EARL aim to facilitate the use of FDG PET as a quantitative imaging biomarker [3, 4].
A detailed discussion on 89Zr physics in PET has been published by Conti et al. [5].
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The aim of this study was to investigate the variability in quantitative performance
and feasibility of quantitative harmonisation in 89Zr PET/CT imaging.
Materials and methods
Investigated systems and phantom experiments
Eight PET/CT systems (system 1–8), calibrated according to the manufacturer’s in-
structions, while also participating and accredited in the EANM/EARL [18F]FDG PET/
CT accreditation programme, were selected for this study. The investigated systems
were two General Electric Discovery 690, two General Electric Discovery 710, one Sie-
mens Biograph 40 mCT, one Siemens Biograph 64 mCT, one Siemens Somatom Defin-
ition AS mCT and one Philips Ingenuity TF.
Two phantom experiments were carried out in accordance with EANM/EARL guide-
lines—Calibration QC and NEMA Phantom QC—where [18F]FDG was substituted with
a 89Zr calibration sample. In the first experiment, a uniform cylindrical phantom was
filled with a solution containing 8–12 kBq/mL of 89Zr. In the second experiment, the
NEMA NU2-2007 body phantom background compartment and spheres were filled
with a 89Zr solution of 2 kBq/mL and 20 kBq/mL, respectively, so as a 10:1 sphere to
background ratio can be achieved (Fig. 1). Exact amount of 89Zr activity was measured
for each scan using only local dose calibrators, which had not underwent specific
cross-calibration for 89Zr. In both experiments, the phantoms underwent a low-dose
CT acquisition followed by PET acquisition of two consecutive bed positions of 5 min
each. Images were reconstructed using EARL-compliant parameters routinely used by
the corresponding sites for [18F]FDG quantitative imaging (Table 1).
Data analysis
Reconstructed DICOM images were analysed using the EARL semi-automatic tool [3, 6] de-
signed for quantitative analysis of images of uniform and NEMA NU2-2007 body phantoms.
From the uniform phantom and the NEMA body phantom’s uniform background
Fig. 1 Transversal slice of 89Zr-filled NEMA NU2-2007 body phantom
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compartment, SUV accuracies for each system were determined. From the NEMA body
phantom experiments, recovery coefficients (RC) were calculated as a function of sphere
sizes, defined as ratio of activity concentration estimated from PET images to the expected
activity concentration measured by dose calibrator. Different RC metric values were calcu-
lated based on 50% background-corrected isocontour VOI (SUVmean), maximum voxel
value included in VOI (SUVmax) and spherical VOI with a diameter of 12 mm, positioned
so as to yield the highest uptake (SUVpeak) [6–8]. Using data from the EARL database, rele-
vant FDG RC curves of the corresponding scanners are displayed as a reference.
Additionally, RC curves were rescaled to correct for a global SUV bias, derived from
the phantom’s background compartment, to mitigate the impact of cross-calibration
error between PET/CT system and dose calibrator on the observed RC. In order to
directly compare the RC curves’ shapes of all systems, the individual recovery coeffi-
cients of the NEMA body phantom spheres were normalised to the recovery coefficient
of the largest (37 mm) sphere.
Results
The SUV bias from both phantom experiments is presented in Fig. 2. The results for
SUVmean, SUVmax and SUVpeak together with corresponding information for EARL
[18F]FDG can be seen in Fig. 3, while the results corrected for SUV bias calculated from
the body phantom background are presented in Fig. 4. Figure 5 demonstrates the RC
curves normalised to the largest 37-mm sphere recovery.
Discussion
In order to remain in the optimal measurement range of the dose calibrators, the 89Zr
activity used in the study was similar to what is injected to a patient in clinical practice,
Fig. 2 SUV accuracy of the PET scanners relative to the dose calibrator measurements plotted by system number.
Systems 1–2 and 3–4 represent GE scanners Discovery 690 and Discovery 710, respectively; systems 5–6 are
Siemens Biograph 40_mCT and Somatom Definition AS_mCT; system 7 is the Philips Ingenuity TF PET/CT; system
8 is the Siemens Biograph 64_mCT
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resulting in significantly higher activity concentrations in the phantoms compared to
patients (due to the smaller phantom volumes). However, lower counts are expected to
further increase the variability of the results and may have hampered comparing recover-
ies between systems, with current EARL specifications and with those seen with 18F. For
clinical studies, low count rates potentially induce an upward bias when SUVmax is used.
To mitigate this upward bias, SUVpeak is an alternative, which is less sensitive to scanner
variation and image noise, and might therefore be the optimal metric to assess tracer up-
take for 89Zr. Consequently, in our phantom study, we included SUVpeak as well.
In addition to verifying the results of a recent study by Makris et al. [9], current study
investigated the real-life scenario of using only local dose calibrators for 89Zr measure-




Fig. 3 RC curves derived from the 89Zr phantom experiments using SUVmean (a), SUVmax (b) and SUVpeak (c)
quantitative metrics and corresponding RC curves derived from the EARL [18F]FDG phantom experiments using
SUVmean (d), SUVmax (e) and SUVpeak (f) quantitative metrics. Current EARL specifications for [18F]FDG-PET/CT
accreditation are presented as bold dashed lines. Systems 1–2 and 3–4 represent GE scanners Discovery 690
and Discovery 710, respectively; systems 5–6 are Siemens Biograph 40_mCT and Somatom Definition AS_mCT;
system 7 is the Philips Ingenuity TF PET/CT; system 8 is the Siemens Biograph 64_mCT
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provided manuals and instructions. Out of the eight systems investigated in total, four
Calibration QC and three NEMA Phantom QC experiments demonstrate a SUV bias
of > 10% (Fig. 2). Since the scanners are EARL accredited for [18F]FDG-PET/CT, they
comply with accreditation specifications for SUV bias (≤ 10%); it is therefore believed
that the large global errors are due to inaccurate cross-calibration between the scanners
and dose calibrators used to measure the 89Zr solution activity on site. While each of
the dose calibrators should be set up by the manufacturer to accurately measure 89Zr,
the results from our study underline the importance of a traceable calibration perform-
ance of dose calibrators used in 89Zr quantitative PET/CT imaging.
From Fig. 2, it can be seen that SUV bias values derived from Calibration QC and
NEMA Phantom QC background agree reasonably well, with the exception of only sys-
tem 3 and to some extent system 4. These inconsistencies as well as the variable bias in
RC curves (Fig. 3) are suggested to be related to activity measurement and phantom
filling procedures on site.
The initial RC curves derived from the images (Fig. 3, a–c) demonstrate increased
spread compared to the background-corrected ones (Fig. 4). After applying the SUV bias
correction, the RC values of five systems show good alignment with each other and with
EANM specifications for [18F]FDG. Two of the investigated systems (1 and 7) remain out
of specifications even after correcting for SUV bias. The reason for this is unknown and
would need further investigation. RC curves normalised to the largest (37 mm) sphere




Fig. 4 Background SUV bias-corrected RC curves derived from the phantom experiments using SUVmean
(a), SUVmax (b) and SUVpeak (c) quantitative metrics. Current EARL specifications for [18F]FDG-PET/CT
accreditation are presented as bold dashed lines. Systems 1–2 and 3–4 represent GE scanners Discovery 690
and Discovery 710, respectively; systems 5–6 are Siemens Biograph 40_mCT and Somatom Definition
AS_mCT; system 7 is the Philips Ingenuity TF PET/CT; system 8 is the Siemens Biograph 64_mCT
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suggest that, with further adjustment—meaning reduction of global SUV bias based on
Calibration QC experiment data and possibly minor adjustment of the image reconstruc-
tion parameters—all of the systems should be able to achieve harmonisation.
The closest alignment of the RC curves can be observed when SUVpeak is used. This
demonstrates the potential of this metric being used when quantitative harmonisation
is desired. It should however be noted that with the use of SUVpeak, one should expect
a decrease in overall contrast recovery, compared to SUVmax.
Finally, with the shape of 89Zr RC curves shown to be similar to 18F in our pilot study,
further harmonisation efforts could be focused on the cross-calibration of the dose calibra-
tors, which is considered to be the largest source of uncertainty in this case. A future 89Zr
harmonisation scheme could therefore be based on a 89Zr dose calibrator cross-calibration
quality control, with a successful site [18F]FDG EARL accreditation being a prerequisite.
Conclusions
All eight investigated systems demonstrated similarly shaped RC curves, and five of
them exhibited close alignment when SUV bias correction was applied. Use of SUV-
peak as a metric, which proved to be the least sensitive to noise and reconstruction
differences among systems, is strongly recommended for multicentre quantitative 89Zr
studies. When PET/CT and dose calibrator cross-calibration procedures are closely
followed and the image reconstruction parameters adjusted, the quantitative harmon-
isation of scanners for 89Zr PET studies is feasible. Yet, our results demonstrate the
urgent need to set up a suitable cross-calibration and accreditation programme to




Fig. 5 RC curves normalised to the largest sphere, derived from the phantom experiments using SUVmean
(a), SUVmax (b) and SUVpeak (c) quantitative metrics. Systems 1–2 and 3–4 represent GE scanners Discovery
690 and Discovery 710, respectively; systems 5–6 are Siemens Biograph 40_mCT and Somatom Definition
AS_mCT; system 7 is the Philips Ingenuity TF PET/CT; system 8 is the Siemens Biograph 64_mCT
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